JP2002542296A - 抗腫瘍剤の効力を増大させる方法 - Google Patents

抗腫瘍剤の効力を増大させる方法

Info

Publication number
JP2002542296A
JP2002542296A JP2000613446A JP2000613446A JP2002542296A JP 2002542296 A JP2002542296 A JP 2002542296A JP 2000613446 A JP2000613446 A JP 2000613446A JP 2000613446 A JP2000613446 A JP 2000613446A JP 2002542296 A JP2002542296 A JP 2002542296A
Authority
JP
Japan
Prior art keywords
cisplatin
hematocrit
agent
tumor
epo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000613446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542296A5 (enExample
Inventor
ピヴァー，エム．，スティーブン
シルヴァー，デービッド，エフ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of JP2002542296A publication Critical patent/JP2002542296A/ja
Publication of JP2002542296A5 publication Critical patent/JP2002542296A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
JP2000613446A 1999-04-27 2000-04-24 抗腫瘍剤の効力を増大させる方法 Pending JP2002542296A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300,124 1999-04-27
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
JP2002542296A true JP2002542296A (ja) 2002-12-10
JP2002542296A5 JP2002542296A5 (enExample) 2007-06-28

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000613446A Pending JP2002542296A (ja) 1999-04-27 2000-04-24 抗腫瘍剤の効力を増大させる方法

Country Status (18)

Country Link
US (3) US6171620B1 (enExample)
EP (1) EP1212068A4 (enExample)
JP (1) JP2002542296A (enExample)
KR (1) KR100693796B1 (enExample)
CN (1) CN1188137C (enExample)
AU (1) AU781301B2 (enExample)
BG (1) BG64940B1 (enExample)
BR (1) BR0010082A (enExample)
CA (1) CA2368618C (enExample)
HU (1) HUP0200840A3 (enExample)
IL (1) IL146012A0 (enExample)
MX (1) MXPA01010899A (enExample)
NO (1) NO20015227L (enExample)
NZ (1) NZ514521A (enExample)
PL (1) PL350918A1 (enExample)
RU (1) RU2271829C2 (enExample)
WO (1) WO2000064455A1 (enExample)
ZA (1) ZA200108012B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019083023A1 (ja) * 2017-10-26 2019-05-02 国立大学法人筑波大学 癌の治療に使用するための組成物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
IL152428A0 (en) 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
MX2009010515A (es) 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0296535A (ja) * 1988-03-03 1990-04-09 Chugai Pharmaceut Co Ltd 骨髄機能障害性貧血治療剤
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
WO1998010650A1 (en) * 1996-09-11 1998-03-19 East Carolina University Method of treating endothelial injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0296535A (ja) * 1988-03-03 1990-04-09 Chugai Pharmaceut Co Ltd 骨髄機能障害性貧血治療剤
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
WO1998010650A1 (en) * 1996-09-11 1998-03-19 East Carolina University Method of treating endothelial injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019083023A1 (ja) * 2017-10-26 2019-05-02 国立大学法人筑波大学 癌の治療に使用するための組成物

Also Published As

Publication number Publication date
CA2368618A1 (en) 2000-11-02
US6171620B1 (en) 2001-01-09
HUP0200840A3 (en) 2003-04-28
US6620779B2 (en) 2003-09-16
US20010000730A1 (en) 2001-05-03
CN1352561A (zh) 2002-06-05
CN1188137C (zh) 2005-02-09
PL350918A1 (en) 2003-02-10
RU2271829C2 (ru) 2006-03-20
KR100693796B1 (ko) 2007-03-12
MXPA01010899A (es) 2003-06-24
AU4486300A (en) 2000-11-10
CA2368618C (en) 2011-03-01
AU781301B2 (en) 2005-05-12
NO20015227L (no) 2001-12-27
BR0010082A (pt) 2002-01-15
KR20020000557A (ko) 2002-01-05
HUP0200840A2 (hu) 2002-07-29
NZ514521A (en) 2003-07-25
BG106057A (en) 2002-04-30
BG64940B1 (bg) 2006-10-31
NO20015227D0 (no) 2001-10-25
EP1212068A4 (en) 2007-03-14
US6426094B2 (en) 2002-07-30
ZA200108012B (en) 2003-03-26
IL146012A0 (en) 2002-07-25
US20020198153A1 (en) 2002-12-26
EP1212068A1 (en) 2002-06-12
WO2000064455A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
JP2002542296A (ja) 抗腫瘍剤の効力を増大させる方法
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
JP2003504413A (ja) 抗腫瘍物質を含む組み合わせ調製物
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
JP2002543112A (ja) アントラサイクリン誘導体を含有する配合製剤
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
CA2836385A1 (en) Method for treatment of advanced solid tumors
KR20080030559A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물
TWI469776B (zh) 有助於癌症之治療的方法，組成物以及製品
CA2437768A1 (en) Targetted anti-tumor drug delivery systems
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
KR101964169B1 (ko) 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제
JPWO2022074124A5 (enExample)
CN112168971B (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
EP3965734A1 (en) Method for increasing cancer patient's haemoglobin level
WO2024216238A2 (en) Use of beta-catenin antagonist and immunomodulator
KR20240138493A (ko) Met 저해제 및 k-ras 저해제를 포함하는 암 예방 또는 치료용 조성물
JP2002537334A (ja) 相乗作用性抗腫瘍組成物
Martinelli et al. Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
KR20100016392A (ko) 암의 치료에 기여하는 조성물 및 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070416

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070416

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101006